VIGL Insider Transactions
| Transaction Date (SEC Report) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2024-03-18 | Kaufmann Petra | officer: Chief Medical Officer | 330,000 | A-Award | A | 330,000 | 3.14 | 1,036,200.00 |
| 2024-03-18 | Kaufmann Petra | 0 | 0 | 0.00 | 0.00 | |||
| 2024-03-01 | Booth Bruce | director | 34,612 | A-Award | A | 34,612 | 3.39 | 117,335.00 |
| 2024-03-01 | Bruhn Suzanne Louise | director | 24,073 | A-Award | A | 24,073 | 3.39 | 81,607.00 |
| 2024-03-01 | Blanchard Cheryl R | director | 24,761 | A-Award | A | 24,761 | 3.39 | 83,940.00 |
| 2024-03-01 | Verni Christopher | officer: General Counsel | 116,000 | A-Award | A | 116,000 | 3.39 | 393,240.00 |
| 2024-03-01 | Ziolkowski Jennifer Lynn | officer: Chief Financial Officer | 156,000 | A-Award | A | 156,000 | 3.39 | 528,840.00 |
| 2024-03-01 | Magovcevic-Liebisch Ivana | director, officer: President and CEO | 463,000 | A-Award | A | 463,000 | 3.39 | 1,569,570.00 |
| 2024-03-01 | Gray David L. F. | officer: Chief Science Officer | 125,000 | A-Award | A | 125,000 | 3.39 | 423,750.00 |
| 2023-11-20 | Magovcevic-Liebisch Ivana | director, officer: President and CEO | 207,687 | P-Purchase | A | 4,000 | 3.75 | 15,000.00 |
| 2023-08-07 | Silber Christopher | officer: Chief Medical Officer | 330,000 | A-Award | A | 330,000 | 6.16 | 2,032,800.00 |
| 2023-08-07 | Silber Christopher | officer | 0 | 0 | 0.00 | 0.00 | ||
| 2023-06-07 | Bruhn Suzanne Louise | director | 13,928 | A-Award | A | 13,928 | 10.00 | 139,280.00 |
| 2023-06-07 | Thistle Mary | director | 13,928 | A-Award | A | 13,928 | 10.00 | 139,280.00 |
| 2023-06-07 | Koenig Gerhard | director | 13,928 | A-Award | A | 13,928 | 10.00 | 139,280.00 |
| 2023-06-07 | Blanchard Cheryl R | director | 13,928 | A-Award | A | 13,928 | 10.00 | 139,280.00 |
| 2023-06-07 | Vitorovic Stefan | director | 13,928 | A-Award | A | 13,928 | 10.00 | 139,280.00 |
| 2023-06-07 | Booth Bruce | director | 13,928 | A-Award | A | 13,928 | 10.00 | 139,280.00 |
| 2023-06-07 | Budd Haeberlein Samantha L. | director | 13,928 | A-Award | A | 13,928 | 10.00 | 139,280.00 |
| 2023-05-08 | Budd Haeberlein Samantha L. | director | 30,694 | A-Award | A | 30,694 | 9.65 | 296,197.00 |
| 2023-05-08 | Budd Haeberlein Samantha L. | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2023-03-01 | Magovcevic-Liebisch Ivana | director, officer: President and CEO | 370,000 | A-Award | A | 370,000 | 11.87 | 4,391,900.00 |
| 2023-03-01 | Bruhn Suzanne Louise | director | 6,235 | A-Award | A | 6,235 | 11.87 | 74,009.00 |
| 2023-03-01 | Booth Bruce | director | 9,713 | A-Award | A | 9,713 | 11.87 | 115,293.00 |
| 2023-03-01 | Verni Christopher | officer: General Counsel | 85,000 | A-Award | A | 85,000 | 11.87 | 1,008,950.00 |
| 2023-03-01 | Thackaberry Evan | officer: SVP, Head of Early Development | 65,000 | A-Award | A | 65,000 | 11.87 | 771,550.00 |
| 2023-03-01 | Blanchard Cheryl R | director | 6,432 | A-Award | A | 6,432 | 11.87 | 76,348.00 |
| 2023-03-01 | Ziolkowski Jennifer Lynn | officer: Chief Financial Officer | 135,000 | A-Award | A | 135,000 | 11.87 | 1,602,450.00 |
| 2023-02-27 | Gray David L. F. | officer: Chief Science Officer | 267,000 | A-Award | A | 267,000 | 12.09 | 3,228,030.00 |
| 2023-02-27 | Gray David L. F. | officer | 0 | 0 | 0.00 | 0.00 | ||
| 2022-11-18 | Papapetropoulos Spyros | officer: Chief Medical Officer | 149,604 | M-Exempt | D | 300 | 0.00 | 0.00 |
| 2022-11-18 | Papapetropoulos Spyros | officer: Chief Medical Officer | 4,300 | M-Exempt | A | 300 | 1.89 | 567.00 |
| 2022-11-18 | Papapetropoulos Spyros | officer: Chief Medical Officer | 4,000 | S-Sale | D | 300 | 14.00 | 4,200.00 |
| 2022-07-27 | Bruhn Suzanne Louise | director: | 24,310 | A-Award | A | 24,310 | 0.00 | 0.00 |
| 2022-07-27 | Bruhn Suzanne Louise | director | 24,310 | A-Award | A | 24,310 | 6.93 | 168,468.00 |
| 2022-07-27 | Bruhn Suzanne Louise | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2022-06-09 | Vitorovic Stefan | director: | 12,155 | A-Award | A | 12,155 | 0.00 | 0.00 |
| 2022-06-09 | Vitorovic Stefan | director | 12,155 | A-Award | A | 12,155 | 3.10 | 37,680.00 |
| 2022-06-09 | Blanchard Cheryl R | director: | 12,155 | A-Award | A | 12,155 | 0.00 | 0.00 |
| 2022-06-09 | Koenig Gerhard | director: | 12,155 | A-Award | A | 12,155 | 0.00 | 0.00 |
| 2022-06-09 | Blanchard Cheryl R | director | 12,155 | A-Award | A | 12,155 | 3.10 | 37,680.00 |
| 2022-06-09 | Booth Bruce | director: | 12,155 | A-Award | A | 12,155 | 0.00 | 0.00 |
| 2022-06-09 | Booth Bruce | director | 12,155 | A-Award | A | 12,155 | 3.10 | 37,680.00 |
| 2022-06-09 | Thistle Mary | director: | 12,155 | A-Award | A | 12,155 | 0.00 | 0.00 |
| 2022-06-09 | Thistle Mary | director | 12,155 | A-Award | A | 12,155 | 3.10 | 37,680.00 |
| 2022-05-16 | Thorp Clay | director: | 1,556,030 | P-Purchase | A | 14,893 | 2.97 | 44,189.00 |
| 2022-05-05 | Thackaberry Evan | officer: SVP, Head of Early Development | 1,500 | P-Purchase | A | 1,500 | 4.00 | 6,000.00 |
| 2022-05-03 | Verni Christopher | officer: General Counsel | 4,000 | P-Purchase | A | 4,000 | 3.77 | 15,074.00 |
| 2022-05-03 | Magovcevic-Liebisch Ivana | director, officer: President and CEO | 203,687 | P-Purchase | A | 1,000 | 3.94 | 3,940.00 |
| 2022-05-02 | Magovcevic-Liebisch Ivana | officer: President and CEO | 202,687 | P-Purchase | A | 4,000 | 3.61 | 14,439.00 |
| 2022-05-03 | Ziolkowski Jennifer Lynn | officer: Chief Financial Officer | 4,000 | P-Purchase | A | 4,000 | 3.77 | 15,098.00 |
| 2022-05-03 | Papapetropoulos Spyros | officer: Chief Medical Officer | 4,000 | P-Purchase | A | 4,000 | 3.40 | 13,591.00 |
| 2022-04-19 | Verni Christopher | officer: General Counsel | 150,000 | A-Award | A | 150,000 | 0.00 | 0.00 |
| 2022-04-19 | Verni Christopher | officer | 0 | 0 | 0.00 | 0.00 | ||
| 2022-04-18 | Thistle Mary | director: | 24,309 | A-Award | A | 24,309 | 0.00 | 0.00 |
| 2022-04-18 | Thistle Mary | director | 24,309 | A-Award | A | 24,309 | 6.80 | 165,301.00 |
| 2022-04-18 | Thistle Mary | director: | 0 | 0 | 0.00 | 0.00 | ||
| 2022-03-28 | Thorp Clay | director: | 3,000 | P-Purchase | A | 3,000 | 7.20 | 21,604.00 |
| 2022-03-01 | Koenig Gerhard | director | 4,351 | A-Award | A | 4,351 | 16.13 | 70,182.00 |
| 2022-03-01 | Magovcevic-Liebisch Ivana | director, officer: President and CEO | 282,000 | A-Award | A | 282,000 | 16.13 | 4,548,660.00 |
| 2022-03-01 | Papapetropoulos Spyridon | officer: Chief Medical Officer | 75,500 | A-Award | A | 75,500 | 16.13 | 1,217,815.00 |
| 2022-03-01 | Booth Bruce | director | 7,577 | A-Award | A | 7,577 | 16.13 | 122,217.00 |
| 2022-03-01 | Booth Bruce | director: | 7,577 | A-Award | A | 7,577 | 9.63 | 72,967.00 |
| 2022-03-01 | Thackaberry Evan | officer: SVP, Head of Early Development | 45,000 | A-Award | A | 45,000 | 0.00 | 0.00 |
| 2022-03-01 | Blanchard Cheryl R | director: | 5,017 | A-Award | A | 5,017 | 9.63 | 48,314.00 |
| 2022-03-01 | Blanchard Cheryl R | director | 5,017 | A-Award | A | 5,017 | 16.13 | 80,924.00 |
| 2022-03-01 | Ziolkowski Jennifer Lynn | officer: Chief Financial Officer | 110,000 | A-Award | A | 110,000 | 0.00 | 0.00 |
| 2022-03-01 | Ziolkowski Jennifer Lynn | officer: Chief Financial Officer | 110,000 | A-Award | A | 110,000 | 16.13 | 1,774,300.00 |
| 2022-01-11 | Cormorant Asset Management, LP | 616,786 | C-Conversion | A | 616,786 | 0.00 | 0.00 | |
| 2022-01-11 | Cormorant Asset Management, LP | 0 | C-Conversion | D | 616,786 | 0.00 | 0.00 | |
| 2022-01-11 | AMGEN INC | 10 percent owner | 3,206,281 | C-Conversion | A | 3,206,281 | 0.00 | 0.00 |
| 2022-01-11 | AMGEN INC | 10 percent owner | 0 | C-Conversion | D | 3,206,281 | 0.00 | 0.00 |
| 2022-01-11 | Thorp Clay | director | 1,519,335 | P-Purchase | A | 265,000 | 14.00 | 3,710,000.00 |
| 2022-01-11 | Thorp Clay | director | 1,254,335 | C-Conversion | A | 1,254,335 | 0.00 | 125.40 |
| 2022-01-11 | Thorp Clay | director | 0 | C-Conversion | D | 2,552,021 | 0.00 | 0.00 |
| 2022-01-11 | Thorp Clay | director | 0 | C-Conversion | D | 926,506 | 0.00 | 0.00 |
| 2022-01-11 | Vida Ventures GP III, L.L.C. | 10 percent owner | 5,004,393 | P-Purchase | A | 1,671,148 | 14.00 | 23,396,072.00 |
| 2022-01-11 | Vida Ventures GP III, L.L.C. | 10 percent owner | 3,333,245 | C-Conversion | A | 3,333,245 | 0.00 | 333.30 |
| 2022-01-11 | Vida Ventures GP III, L.L.C. | 10 percent owner | 11,536 | P-Purchase | A | 3,852 | 14.00 | 53,928.00 |
| 2022-01-11 | Vida Ventures GP III, L.L.C. | 10 percent owner | 7,684 | C-Conversion | A | 7,684 | 0.00 | 0.77 |
| 2022-01-11 | Vida Ventures GP III, L.L.C. | 10 percent owner | 0 | C-Conversion | D | 21,310 | 0.00 | 0.00 |
| 2022-01-11 | Atlas Venture Fund XII, L.P. | 10 percent owner | 4,808,896 | P-Purchase | A | 535,000 | 14.00 | 7,490,000.00 |
| 2022-01-11 | Atlas Venture Fund XII, L.P. | 10 percent owner | 4,273,896 | C-Conversion | A | 2,831,520 | 0.00 | 283.20 |
| 2022-01-11 | Atlas Venture Fund XII, L.P. | 10 percent owner | 1,027,978 | C-Conversion | A | 1,027,978 | 0.00 | 102.80 |
| 2022-01-11 | Atlas Venture Fund XII, L.P. | 10 percent owner | 0 | C-Conversion | D | 7,852,374 | 0.00 | 0.00 |
| 2022-01-11 | Atlas Venture Fund XII, L.P. | 10 percent owner | 0 | C-Conversion | D | 2,850,789 | 0.00 | 0.00 |
| 2022-01-11 | Booth Bruce | director | 4,808,896 | P-Purchase | A | 535,000 | 14.00 | 7,490,000.00 |
| 2022-01-11 | Booth Bruce | director | 4,273,896 | C-Conversion | A | 2,831,520 | 0.00 | 283.20 |
| 2022-01-11 | Booth Bruce | director | 1,027,978 | C-Conversion | A | 1,027,978 | 0.00 | 102.80 |
| 2022-01-11 | Booth Bruce | director | 0 | C-Conversion | D | 7,852,374 | 0.00 | 0.00 |
| 2022-01-11 | Booth Bruce | director | 0 | C-Conversion | D | 2,850,789 | 0.00 | 0.00 |
| 2022-01-11 | Vitorovic Stefan | director | 5,004,393 | P-Purchase | A | 1,671,148 | 14.00 | 23,396,072.00 |
| 2022-01-11 | Vitorovic Stefan | director | 3,333,245 | C-Conversion | A | 3,333,245 | 0.00 | 333.30 |
| 2022-01-11 | Vitorovic Stefan | director | 11,536 | P-Purchase | A | 3,852 | 14.00 | 53,928.00 |
| 2022-01-11 | Vitorovic Stefan | director | 7,684 | C-Conversion | A | 7,684 | 0.00 | 0.77 |
| 2022-01-11 | Vitorovic Stefan | director | 0 | C-Conversion | D | 21,310 | 0.00 | 0.00 |
| 2022-01-11 | Northpond Ventures GP, LLC | 10 percent owner | 2,831,520 | C-Conversion | A | 2,831,520 | 0.00 | 283.20 |
| 2022-01-11 | Northpond Ventures GP, LLC | 10 percent owner | 1,382,978 | P-Purchase | A | 355,000 | 14.00 | 4,970,000.00 |
| 2022-01-11 | Northpond Ventures GP, LLC | 10 percent owner | 1,027,978 | C-Conversion | A | 1,027,978 | 0.00 | 102.80 |
| 2022-01-11 | Northpond Ventures GP, LLC | 10 percent owner | 0 | C-Conversion | D | 2,831,520 | 0.00 | 0.00 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
